Answer
Pedmarqsi is licensed to reduce the risk of cisplatin-related hearing damage in eligible children and young people with localised, non-metastatic solid tumours.
Sources for this answer
- Pedmarqsi 80 mg/mL solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.